The national palliative care guidelines make recommendations about the use of various drugs. These recommendations should be considered alongside the information contained below.
Within these guidelines, where the use of medicines falls outside a marketing authorisation, the drugs will be identified with the symbol .
The Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK grants a marketing authorisation (licence) for medical products (http://www.mhra.gov.uk/Howweregulate/index.htm ). The purpose of the authorisation is to provide the quality standard for safe medicines use and to regulate the activity of the pharmaceutical company for marketing, distribution and supply of the drug. This does not restrict the prescription of the drug by appropriately qualified prescribers. Authorised drugs can be used legally in clinical situations that fall outside the remit of the authorisation (referred to as 'off-label' or ‘off-licence’), for example for a different age group, a different indication, a different dose or route or method of administration, mixing medicines for administration via syringe pump. Use of "unlicensed" drugs refers to those products that have no licence for any clinical situation although they may be in the process of evaluation leading to such authorisation.
‘Named Patient Medicines’ is the term used to describe the use of an unlicensed medicine to meet the special needs of an individual patient (e.g. Levomepromazine 6mg tablets). There are various reasons why a company would consider named-patient supply e.g. if the product is not licensed in Europe, but has gained marketing approval elsewhere in the world and the company wants to control 'usage' of their medication. Pharmaceutical companies can supply a pre-launch medicine on a specific and strict named-patient basis. This allows patients to benefit from the drug as early as possible in pre-launch phase and enables prescribers to gain familiarity with the new product.
‘Special Medicines’ often referred to as ‘specials’ are medicines which are prepared by a pharmacist or manufacturer in response to a prescription for an individual patient for whom a licensed product is not available. It is a bespoke or specially prepared product manufactured to meet a specific patient's specific needs. Specials are manufactured in MHRA licensed NHS units or commercial manufacturing units and each unit must comply with a number of legal, regulatory and quality requirements. Batch manufactured products are usually supplied with a certificate of analysis (e.g. alfentanil spray 5mg in 5ml for buccal or intranasal use).
When generic equivalents of medicines are awarded marketing authorisations, the equivalence is only required to be demonstrated for licensed uses. Therefore previously helpful off-label uses cannot be assumed e.g. the off-label sublingual route of administration of oral lorazepam tablets. There are a limited number of products which display the relevant characteristics for sublingual administration and if the incorrect manufacturer supply is provided apparent medication failure can result. Prescribers require to be vigilant to such changes when using medicine off-label.
It is important to note that the Patient Information Leaflet supplied with dispensed medicines will not contain information on any off-label use.
The intended indication/need for use of the medicine in an unlicensed manner or unlicensed preparation should be stated on the prescription (EU Directive 2001/83/EC and Human Medicines regulations 2012).
Recommendations from bodies such as the General Medical Council and the medical defence organisations place a duty on doctors (and equivalents for non-medical prescribers) to act responsibly and to provide information to patients on the nature and associated risks of any treatment, including 'off-label' and unlicensed drugs.
Guidance also recommends that such drugs are prescribed following informed consent by the patient, and that this decision is recorded in the patient’s notes. This may not be practical in palliative care where the use of 'off-label' medication is commonplace.
The recommendations of the Association for Palliative Medicine and The Pain Society include the following:
‘The use of drugs 'off-label' should be seen as a legitimate aspect of clinical care. It is both necessary and common.’
‘Informed consent should be obtained from the patient whenever possible outlining identifiable risks. This information should be recorded.’
‘Drugs should be selected that offer the best balance of benefit against harm for any given patient.’
‘Audit and research should inform change of practice.’
‘Practice should, as far as possible, be underpinned by evidence and advocated by a responsible body of professional opinion.’
‘Health Care Professionals must support the development of national frameworks, guidelines and standards and the provision of accurate, clear and specific information for patients and carers for the use of drugs beyond licence.’
Medicines Information Sheets
It is recognised that some medicines will be initiated by a specialist and care may transfer to a generalist setting. The presentation, indications, doses and routes of administration may be unfamiliar to practitioners and medicines information sheets will be made available. The medicine information sheets will be colour coded to indicate medicines used under specialist guidance and those for more general use.
Red – For medicines normally initiated and used under specialist guidance
Amber – For medicines normally initiated by a specialist but may be used by generalists
Green – For medicines routinely initiated and used by generalists
Medicines and Healthcare Products Regulatory Agency (MHRA) Warnings
The MHRA send regular updates to healthcare professionals to advise about concerns in relation to medicines. There have been a number of recent advisory notices which affect drugs used regularly in palliative care which have resulted in restrictions to prescribed doses or duration of continuous prescribing e.g. metoclopramide, domperidone. Where used in the palliative care setting the use of these products is often off-label. The concerns required to be placed in context of prognosis. e.g. doses of metoclopramide (over 80mg/24hrs) remain effective in the management of intractable nausea because of the putative effect on 5HT receptors in selected, poor prognosis patients or short-term in better prognosis patients.
The Scottish Palliative Care Pharmacists’ Association (SPCPA) will monitor updates and advise the guidelines steering group of warnings relating to medicines within the guidelines.
Adherence to guideline recommendations will not ensure a successful outcome in every case. When considering drug intervention it is the responsibility of all professionals to exercise clinical judgement in the management of individual patients. This should include taking into consideration changes to SPC content and relevant MHRA alerts when reaching a decision about clinical care.
Medicines Prolonging QT Interval
Palliative care patients in general may be at higher risk of a prolonged QT interval given the high prevalence of multiple drug use and metabolic disturbance. A number of drugs used within palliative care may have potential to prolong QT interval. Polypharmacy is common in palliative care, and using more than one drug concurrently increases the risk of drug interactions. A commonsense approach should prevail and the benefit of certain drugs used in the last days of life, e.g. haloperidol, is likely to far outweigh any risk, and an ECG is not required. Prescribing medicines which prolong QT interval for patients in an earlier phase of their disease trajectory should be managed within that context.